Señales en vivo de ACAD | Maximiza tus Ganancias con Getagraph.com

VENDER 117836 min ago

@ $25.78

Emitido: 14 feb 2024 @ 15:32

Retorno: -32.74%

Señal anterior: feb 14 - 13:10

Señal anterior: Comprar

Retorno: 0.72 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 12:29):

Stats
Volumen de hoy	394 917
Volumen promedio	1.82M
Capitalización de mercado	2.86B
EPS	$0 ( 2024-02-27 )
Próxima fecha de ganancias	( $0.170 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-46.86
ATR14	$0.0180 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Schneyer Mark C.	Buy	6 814	Common Stock
2024-05-02	Schneyer Mark C.	Sell	3 503	Common Stock
2024-05-01	Schneyer Mark C.	Sell	6 814	Restricted Stock Units
2024-05-01	Teehan Brendan	Buy	6 814	Common Stock
2024-05-02	Teehan Brendan	Sell	3 477	Common Stock

INSIDER POWER
27.64
Last 98 transactions
Buy: 1 140 321 \| Sell: 756 729

Volumen Correlación

Largo: -0.06 (neutral)

Corto: -0.99 (very strong negative)

Signal:(60.073) Neutral

ACADIA Pharmaceuticals Correlación

10 Correlaciones Más Positivas
RRGB	0.956
AUUD	0.944
SVC	0.943
LPSN	0.941
TTEC	0.941
SONN	0.938
BGXX	0.936
RDUS	0.936
BMBL	0.935
AKTS	0.935

10 Correlaciones Más Negativas
TUEM	-0.954
ACGL	-0.946
GRCL	-0.94
RETA	-0.937
LCA	-0.936
USCB	-0.933
GHRS	-0.93
GXII	-0.929
MSDA	-0.928
XLRN	-0.928

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ACADIA Pharmaceuticals Correlación - Moneda/Commodity

0.13
( neutral )

0.12
( neutral )

0.00
( neutral )

0.24
( neutral )

0.08
( neutral )

-0.15
( neutral )

ACADIA Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$726.44M
Beneficio Bruto:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2023
Ingresos:	$726.44M
Beneficio Bruto:	$680.71M (93.70 %)
EPS:	$-0.370

FY	2022
Ingresos:	$517.24M
Beneficio Bruto:	$507.07M (98.03 %)
EPS:	$-1.340

FY	2021
Ingresos:	$484.15M
Beneficio Bruto:	$465.00M (96.05 %)
EPS:	$-1.067

Financial Reports:

No articles found.

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Actualizaciones en tiempo real para ACADIA Pharmaceuticals [ACAD]

Upcoming Earnings Alert